Positive results for another Humira biosimilar

29 November 2016
biosimilars_samples_large

The line-up of near-term biosimilar competitors to AbbVie’s (NYSE: ABBV) blockbuster Humira (adalimumab) – which generates annual sales of some $15 billion - is getting ever longer, even as the originator is still expressing confidence on its intellectual property protecting its market exclusivity.

Just today, Momenta Pharmaceuticals (Nasdaq: MNTA) announced that the confirmatory Phase III clinical study of M923, a biosimilar Humira candidate developed in collaboration with Baxalta, now part of Ireland-headquartered rare disease drug specialist Shire (LSE: SHP), in patients with moderate-to-severe chronic plaque psoriasis, met its primary endpoint.

Momenta’s shares were up 7.9% to $15.00 in pre-market trading.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars